Oral Asciminib in CML
Contact
Description
This study involves taking a study drug called asciminib. The overall goal of the study is to find out how safe and effective the study drug is in treating people that have been diagnosed with Chronic Myeloid Leukemia (CML) and have not responded to treatment.
Eligibility and criteria
IRB Number:
24-021950
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
The study will enroll patients between 1 and less than 18 years of age that have been diagnosed with Chronic Myeloid Leukemia (CML) and have not responded to treatment. Participants in this research will:
- Receive a study drug called asciminib
- Have research blood tests
- Have dual-energy x-ray absorptiometry (DEXA) scans
- Have electrocardiograms (ECGs)
- Have echocardiograms (ECHOs)
- Complete questionnaires
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.